REFERENCES:

Acknowledgements: NIL.
Disclosure of Interests: None Declared.
DOI: 10.1136/annrheumdis-2023-eular.2933

Figure 1. Skin lesions. Heliotrope rash involving the face including the nasolabial folds, V-neck sign, vasculitis with microhemorrhages, periungual erythema, Gottron’s papules, extensive vitiligo.

Acknowledgements: NIL.
Disclosure of Interests: Antonio Tonutti: None declared, Nicoletta Luciano: None declared, Angelo Ceribelli: None declared, Arianna Sonaglia: None declared, Daniela Renna: None declared, Alessandro Repici: None declared, Andrea Lania Consultant of: Ipsen, Grant/research support from: Pfizer, Ana Lleó: None declared, Stella De Nicola: None declared, Paolo Morelli: None declared, Marco Pagani: None declared, Carlo Selmi Consultant of: AbbVie, Amgen, Alfa-Wassermann, Biogen, Eli-Lilly, Galapagos, Janssen, Novartis, Pfizer, SOBI, Grant/research support from: AbbVie, Amgen, Pfizer, Maria De Santis: None declared.
DOI: 10.1136/annrheumdis-2023-eular.3685

Patient information and education.

POS0577-PARE EVALUATION OF PATIENT SATISFACTION WITH REMOTE SELF-INJECTION TRAINING: A SINGLE-CENTRE PATIENT-REPORTED SURVEY

Keywords: Inflammatory arthritides, Patient reported outcomes, Patient information and education

S. McCourt1, M. Andiappan2, 1Southern Health and Social Care Trust, Rheumatology, Craigavon, United Kingdom; 2Open Health, Real World Evidence, Marlow, United Kingdom

Background: Subcutaneous self-injection of methotrexate (SC MTX) is used for the treatment of several inflammatory diseases. All newly initiated patients should be educated and trained in the proper injection technique by their healthcare provider (HCP), with the first injection performed under medical supervision. This training has typically been conducted during face-to-face consultations, however since the start of the COVID-19 pandemic it has been necessary to conduct training remotely due to the cancellation of clinics.

Objectives: To understand patient-reported experiences and satisfaction with remote SC MTX self-injection training.

Methods: A cross-sectional electronic survey was administered between 11 October 2022 and 30 November 2022 to patients at Southern Health and Social Care Trust who had recently been trained via telephone or video conference (VC) on how to self-inject methotrexate using a pre-filled, auto-injector pen. Patients were aged ≥18 with a range of arthritis types, including rheumatoid, psoriatic, polyarticular juvenile idiopathic and chronic reactive inflammatory arthritis. Remote training was delivered by the patient’s nurse as per routine practice (independently of this survey). Patients were sent a patient information pack (PIP) prior to the training consultation. During the training, the nurse discussed the process of injecting with the auto-injector pen before virtually supervising the first injection. The survey consisted of 14 questions; topics included experiences and satisfaction with preparation for the HCP appointment, the training consultation and post-training experiences and preferences. The responses were analysed descriptively on an item-by-item basis.

Results: In total 73 patients completed the survey; 77% (n=56/73) were female, and 96% (n=70/73) had no prior experience with a SC MTX auto-injector pen. The training was completed by telephone for 92% (n=67/73) of patients and by VC for 8% (n=6/73). 99% (n=72/73) received a PIP in advance of their training consultation and 92% (n=67/73) received this by post. 67% (n=49/73) of patients